Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rosopatamab 225Ac - Dominari Holdings

Next Previous
Drug Profile

Rosopatamab 225Ac - Dominari Holdings

Alternative Names: 225Ac-J591; Actinium-225 radiolabeled J591; CONV 01-α; J591 - Dominari Holdings

Latest Information Update: 17 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Convergent Therapeutics; Weill Cornell Medicine
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 10 Feb 2025 Efficacy data from a phase I/II trial in Prostate cancer released by Convergent Therapeutics
  • 16 Oct 2024 Weill Medical College of Cornell University and Merck Sharp & Dohme re-initiates a phase I/II trial in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy) in USA (IV) (NCT04946370)
  • 13 Sep 2024 Efficacy and adverse events data from a phase I/II trial in Prostate cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top